This strategy would mean shifting the treatment paradigm from ACE inhibitors to angiotensin II receptor type 1 blockers and reducing the amount of inappropriate β-blocker use in the absence of coronary heart disease or heart failure with reduced ejection fraction, which was estimated to be prescribed as initial monotherapy for hypertension in up to 20% of older adults without compelling indication (ie, coronary artery disease, systolic heart failure, or atrial fibrillation).40 The gene discussed is AGTR1; the disease is coronary artery disorder.